Dr Vimal S Lala, DO | |
7230 Medical Center Dr, Suite 500, West Hills, CA 91307-1907 | |
(818) 348-7246 | |
(818) 348-7248 |
Full Name | Dr Vimal S Lala |
---|---|
Gender | Male |
Speciality | Anesthesiology |
Experience | 22 Years |
Location | 7230 Medical Center Dr, West Hills, California |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1205996501 | NPI | - | NPPES |
Facility Name | Location | Facility Type |
---|---|---|
Cedars-sinai Medical Center | Los angeles, CA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Advanced Pain Medical Group, Inc. | 1557461597 | 3 |
News Archive
HemoGenix announced today that FDA CBER has given HemoGenix its first Master File Number for an in vitro blood stem cell potency, quality and release assay (HALO-96 PQR) for cellular therapy products used for stem cell transplantation purposes. HALO-96 PQR is the first commercially available stem cell potency assay for cellular therapy products.
A vaccine against the virus that causes cervical cancer and genital warts could reduce persistent infection and disease by 90%, suggest the results of a randomised trial published online by The Lancet Oncology.
The problem, as numerous experts warned at the time, was whether the program could be run, as the law required, in a way that made it financially solvent for at least 75 years. The difficulty with the CLASS Act was ensuring that premiums could be set low enough to attract widespread participation but high enough to pay tbenefits. The risk was that the program would attract the sickest participants, who thought they might need its protections, and thereby drive premium prices ever higher in a spiral of dysfunctionhe promised.
A new supplemental therapy that teaches pain coping and biofeedback skills can reduce pain, the potential for chronic pain and health-care costs for millions of Americans suffering from a common jaw disorder, UT Southwestern Medical Center researchers have found.
› Verified 9 days ago
Entity Name | Advanced Pain Medical Group, Inc. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1891818951 PECOS PAC ID: 1557461597 Enrollment ID: O20070705000374 |
News Archive
HemoGenix announced today that FDA CBER has given HemoGenix its first Master File Number for an in vitro blood stem cell potency, quality and release assay (HALO-96 PQR) for cellular therapy products used for stem cell transplantation purposes. HALO-96 PQR is the first commercially available stem cell potency assay for cellular therapy products.
A vaccine against the virus that causes cervical cancer and genital warts could reduce persistent infection and disease by 90%, suggest the results of a randomised trial published online by The Lancet Oncology.
The problem, as numerous experts warned at the time, was whether the program could be run, as the law required, in a way that made it financially solvent for at least 75 years. The difficulty with the CLASS Act was ensuring that premiums could be set low enough to attract widespread participation but high enough to pay tbenefits. The risk was that the program would attract the sickest participants, who thought they might need its protections, and thereby drive premium prices ever higher in a spiral of dysfunctionhe promised.
A new supplemental therapy that teaches pain coping and biofeedback skills can reduce pain, the potential for chronic pain and health-care costs for millions of Americans suffering from a common jaw disorder, UT Southwestern Medical Center researchers have found.
› Verified 9 days ago
Entity Name | Advanced Anesthesia Specialists A Medical Corporation |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1871733600 PECOS PAC ID: 0042340705 Enrollment ID: O20100608000088 |
News Archive
HemoGenix announced today that FDA CBER has given HemoGenix its first Master File Number for an in vitro blood stem cell potency, quality and release assay (HALO-96 PQR) for cellular therapy products used for stem cell transplantation purposes. HALO-96 PQR is the first commercially available stem cell potency assay for cellular therapy products.
A vaccine against the virus that causes cervical cancer and genital warts could reduce persistent infection and disease by 90%, suggest the results of a randomised trial published online by The Lancet Oncology.
The problem, as numerous experts warned at the time, was whether the program could be run, as the law required, in a way that made it financially solvent for at least 75 years. The difficulty with the CLASS Act was ensuring that premiums could be set low enough to attract widespread participation but high enough to pay tbenefits. The risk was that the program would attract the sickest participants, who thought they might need its protections, and thereby drive premium prices ever higher in a spiral of dysfunctionhe promised.
A new supplemental therapy that teaches pain coping and biofeedback skills can reduce pain, the potential for chronic pain and health-care costs for millions of Americans suffering from a common jaw disorder, UT Southwestern Medical Center researchers have found.
› Verified 9 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Vimal S Lala, DO 7230 Medical Center Dr, Suite 500, West Hills, CA 91307-1907 Ph: (818) 348-7246 | Dr Vimal S Lala, DO 7230 Medical Center Dr, Suite 500, West Hills, CA 91307-1907 Ph: (818) 348-7246 |
News Archive
HemoGenix announced today that FDA CBER has given HemoGenix its first Master File Number for an in vitro blood stem cell potency, quality and release assay (HALO-96 PQR) for cellular therapy products used for stem cell transplantation purposes. HALO-96 PQR is the first commercially available stem cell potency assay for cellular therapy products.
A vaccine against the virus that causes cervical cancer and genital warts could reduce persistent infection and disease by 90%, suggest the results of a randomised trial published online by The Lancet Oncology.
The problem, as numerous experts warned at the time, was whether the program could be run, as the law required, in a way that made it financially solvent for at least 75 years. The difficulty with the CLASS Act was ensuring that premiums could be set low enough to attract widespread participation but high enough to pay tbenefits. The risk was that the program would attract the sickest participants, who thought they might need its protections, and thereby drive premium prices ever higher in a spiral of dysfunctionhe promised.
A new supplemental therapy that teaches pain coping and biofeedback skills can reduce pain, the potential for chronic pain and health-care costs for millions of Americans suffering from a common jaw disorder, UT Southwestern Medical Center researchers have found.
› Verified 9 days ago